This is very interesting to me.Thing I like about Shigimabs is that the mechanism is very straight forward. This is an anti-toxin and therefore preclinical models should predict efficacy in the clinic which is pretty rare in drug development and a win for TLN.What has always bothered me is that the market is small and unpredictable. If resistent strains were to pop up more in cattle and meat then
...more